Feature Channels: Men's Health

• share
• favorite_border

Production of actinium-227 ramps up for use in a drug to fight prostate cancer that has spread to bone.

• share
• favorite_border

Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more precise and personalized. This work will be a critical component of a new interdisciplinary research project funded with $1.4 million from the National Institutes of Health (NIH) that seeks to improve radiation therapy for high-risk prostate cancer patients.

• share
• favorite_border

In a new study published by European Urology, UCLA researchers and colleagues from ten other institutions examined the protocol for treating aggressive prostate cancer. With aggressive forms of this disease, it is often unclear if radiation therapy should be applied to the prostate alone or to the whole pelvis. The reason a low-dose of radiation may be applied to the whole pelvis is that pelvic lymph nodes may have microscopic cancer cells within them.

• share
• favorite_border

Scientists at the Johns Hopkins Kimmel Center say they have affirmed widespread inconsistencies in the use of a common laboratory procedure called immunohistochemical staining, and say the variations are making many laboratory experiments unreliable.

• share
• favorite_border

A study published recently in the Journal of Clinical Oncology Precision Oncology, an American Society of Clinical Oncology (ASCO) journal, outlines findings from the largest-ever prospective genomic analysis of advanced prostate cancer tumors. Using comprehensive genomic profiling (CGP) to analyze thousands of tumor samples from men with advanced prostate cancers, the researchers identified that 57 percent of the samples evaluated had genomic characteristics that suggested the tumors were candidates for targeted therapies.

• share
• favorite_border

Men who delay starting a family have a ticking “biological clock” — just like women — that may affect the health of their partners and children, according to Rutgers researchers.

• share
• favorite_border

In mouse models and prostate cancer cell lines, researchers at the University of Michigan have demonstrated the preliminary effectiveness of a new set of compounds that offer a potential advance in the treatment of metastatic castration-resistant prostate cancer — one that appears to avoid many of the usual mechanisms of treatment resistance.

• share
• favorite_border

University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

• share
• favorite_border

Investigators at Rutgers Cancer Institute of New Jersey have found that approximately 30 percent of men with localized prostate cancer may have alterations in DNA damage response pathways.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.

• share
• favorite_border

WASHINGTON – Most Americans harbor positive views about mental health disorders and treatment, according to the results of a survey released today, in recognition of mental health month. The survey was conducted by The Harris Poll on behalf of the American Psychological Association.

• share
• favorite_border

UCLA researchers have developed a new artificial intelligence system to help radiologists improve their ability to diagnose prostate cancer. The system, called FocalNet, helps identify and predict the aggressiveness of the disease evaluating magnetic resonance imaging, or MRI, scans, and it does so with nearly the same level of accuracy as experienced radiologists.

• share
• favorite_border

• share
• favorite_border

Prostate cancer patients in Nashville and Los Angeles are benefiting from a computer-based decision aid that implements the latest study results to tailor treatment options to an individual’s quality-of-life priorities.

• share
• favorite_border

University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.

• share
• favorite_border

The rate of human papillomavirus (HPV) infection is high among young minority gay, bisexual, and other men who have sex with men despite the availability of a vaccine that can prevent the infection, a Rutgers School of Public Health study found.

• share
• favorite_border

Researchers in Spain have discovered that a hormone secreted by fat cells that is present at higher levels in women can stop liver cells from becoming cancerous. The study, which will be published April 3 in the ournal of Experimental Medicine, helps explain why hepatocellular carcinoma (HCC) is more common in men, and could lead to new treatments for the disease, which is the fourth leading cause of cancer-related death worldwide.

• share
• favorite_border

Long-term testosterone therapy can help men with hypogonadism lose weight and maintain their weight loss, researchers from Germany and the United States report. Ten-year results of the ongoing study will be presented Monday at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.

• share
• favorite_border

Privacy concerns linked to both health facilities and providers are major barriers to increasing the number of men who are tested and treated for HIV in Cote d’Ivoire, suggests new Johns Hopkins Center for Communication Programs (CCP) research. CCP is based at the Johns Hopkins Bloomberg School of Public Health.

• share
• favorite_border

Decreased sperm and testosterone production caused by abuse of performing-enhancing hormones may be fully reversible once men stop taking the drugs, but full recovery can take at least nine to 18 months, according to research to be presented Sunday, March 24 at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.